Clínica Girona has received recognition within the Luminaries programme of the biomedical company. Quibim for their leadership in the adoption of Artificial Intelligence solutions and for their firm commitment to innovation in the clinical field. 

Clínica Girona receives Quibim's Luminaries recognition for its leadership in the use of artificial intelligence applied to prostate cancer detection.
Clínica Girona receives Quibim's Luminaries recognition for its leadership in the use of artificial intelligence applied to prostate cancer detection.

Specifically, the Magnetic Resonance Imaging service at our centre not only uses the artificial intelligence tool QP-Prostate, which optimises radiologists“ workflows through automated prostate segmentation and the detection of suspicious lesions, but has also clinically validated its use through the study: ”Validation of an AI-computed aided detection system for clinically significant prostate cancer in routine MRI".

This work has confirmed the utility of technology as a supportive tool for detecting clinically significant prostate cancer in routine clinical practice. The results have been disseminated in specialised scientific publications and will be presented at medical congresses.

The photo shows Encarna Sánchez, Vice President of Client Success at Quibim; Sandra Crous, Clinical Resonance Manager at Clínica Girona; Dr. Kai Vilanova, MRI R+D Director at Clínica Girona; and Claire Palacin, Vice President of Marketing and Communication at Quibim.

Back to list
Older Talk on how to care for your skin at Clínica Girona